MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
ESMO Open
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

245 results · 1 filter active ·
Results by year
20162025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
245 works in the cohort · of 4,299,418page 4 of 5

Labels cover 1 of 245 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 245 of 245 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affaboutunlabeled
159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)
Sibylle Loibl, S.M. Tolaney, P. Schmid, Barbara Pistilli, Rebecca Dent, Jamil Asselah +10 more
2024· article· en· ESMO Open· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · metaepi_narrowconsensus · none
1
citations
affunlabeled
114P Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre phase III (neo)adjuvant FeDeriCa study
Christian Jackisch, S-A. Im, André Mattar, Daniil Stroyakovskiy, Zbigniew Nowecki, Michelino De Laurentiis +8 more
2024· article· en· ESMO Open· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
1
citations
affunlabeled
On finding acceptance
David Chen
2023· letter· en· ESMO Open· Medicine
distilled prediction:candidate · metaresearch+research_integrity+insufficient_payloadconsensus · insufficient_payload
1
citations
← previousnext →

How this was built: Screen · Findings · About